Median progression-free survival was 173 months ( 95 % CI 152-202 ) in patients assigned to treatment every 3 weeks , versus 183 months ( 168-209 ) in women allocated to the weekly schedule ( hazard ratio 096 , 95 % CI 080-116 ; p = 066 ) .